Oldest pages

From NeuroRehab.wiki

Showing below up to 50 results in range #351 to #400.

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

  1. DEMENTIA-ALZHEIMER'S Dz MANAGEMENT‏‎ (03:41, 21 February 2023)
  2. CLINICAL-INTERNUCLEAR OPTHALMOPLEGIA‏‎ (03:41, 21 February 2023)
  3. PARKINSONS & PARKINSONISM-PELVIC DYSFUNCTION‏‎ (03:41, 21 February 2023)
  4. NEUROPATHY-CIDP INVESTIGATIONS‏‎ (03:41, 21 February 2023)
  5. CLINICAL-TREMORS‏‎ (03:41, 21 February 2023)
  6. MND-POST POLIO SYNDROME (PPS) DIFFERENTIALS‏‎ (03:41, 21 February 2023)
  7. DIZZINESS-BPPV, PAGNINI-MCCLURE MANOEUVRE‏‎ (03:41, 21 February 2023)
  8. STROKE-EXECUTIVE FUNCTION (NON PHARMACOLOGIC) MGM‏‎ (03:41, 21 February 2023)
  9. COMA-INFRATENTORIAL ETIOLOGY‏‎ (03:41, 21 February 2023)
  10. SEIZURES-STOPPING MEDICATION‏‎ (03:41, 21 February 2023)
  11. MYASTHENIA GRAVIS-MANAGEMENT‏‎ (03:41, 21 February 2023)
  12. CLINICAL-ARGYLL ROBERTSON PUPIL‏‎ (03:41, 21 February 2023)
  13. NCS-EMG (ABNORMAL RESTING MUSCLE ACTIVITY)‏‎ (03:41, 21 February 2023)
  14. GENERALIZED SEIZURE-MANAGEMENT‏‎ (03:41, 21 February 2023)
  15. STROKE-tPA MECHANISM‏‎ (03:41, 21 February 2023)
  16. CLINICAL-NYSTAGMUS‏‎ (03:41, 21 February 2023)
  17. PARKINSONS (MILD TO MODERATE) Tx-MAO B INHIBITOR‏‎ (03:41, 21 February 2023)
  18. NEUROPATHY-PATTERNS OF INVOLVEMENT‏‎ (03:41, 21 February 2023)
  19. CNS INFECTIONS-CJD‏‎ (03:41, 21 February 2023)
  20. MND-VOCATION & FINANCIAL ISSUES‏‎ (03:41, 21 February 2023)
  21. STROKE-BRAIN STIMULATION‏‎ (03:41, 21 February 2023)
  22. TIA-RISK STRATIFICATION (ABCD2 SCORE)‏‎ (03:41, 21 February 2023)
  23. CLINICAL-CAUSES OF ANOSMIA‏‎ (03:41, 21 February 2023)
  24. NCS-MOTOR TESTING PARAMETERS‏‎ (03:41, 21 February 2023)
  25. PARKINSONS & PARKINSONISM-LSVT BIG‏‎ (03:41, 21 February 2023)
  26. STROKE-CT, EARLY FINDINGS‏‎ (03:41, 21 February 2023)
  27. MULTIPLE SCLEROSIS-DEPRESSION‏‎ (03:41, 21 February 2023)
  28. SEIZURES-ANTI EPILEPTIC TERATOGENS‏‎ (03:41, 21 February 2023)
  29. STROKE-MEMORY DEFICIT MANAGEMENT‏‎ (03:41, 21 February 2023)
  30. STROKE-PRESENTATION, MIMICS‏‎ (03:41, 21 February 2023)
  31. NCS-CIP & CIM INVESTIGATIONS‏‎ (03:41, 21 February 2023)
  32. DEMENTIA-ALZHEIMER'S Dz RISK FACTORS‏‎ (03:41, 21 February 2023)
  33. PARKINSONS & PARKINSONISM-PHARMACOLOGIC MGM‏‎ (03:41, 21 February 2023)
  34. NEUROPATHY-CIDP VARIANTS‏‎ (03:41, 21 February 2023)
  35. DERMATOMES-C2 TO C4‏‎ (03:41, 21 February 2023)
  36. MND-POST POLIO SYNDROME (PPS) EXERCISE REGIMEN‏‎ (03:41, 21 February 2023)
  37. DIZZINESS-CAUSES OF VERTIGO‏‎ (03:41, 21 February 2023)
  38. STROKE-FERTILITY‏‎ (03:41, 21 February 2023)
  39. COMA-LOCKED IN SYNDROME‏‎ (03:41, 21 February 2023)
  40. MYASTHENIA GRAVIS-MYAESTHENIC CRISIS‏‎ (03:41, 21 February 2023)
  41. NCS-EMG (MOTOR UNIT ACTION POTENTIAL, MUAP)‏‎ (03:41, 21 February 2023)
  42. STROKE-tPA MEDICATIONS‏‎ (03:41, 21 February 2023)
  43. DEMENTIA-DIAGNOSIS‏‎ (03:41, 21 February 2023)
  44. PARKINSONS (SEVERE) Tx-L DOPA‏‎ (03:41, 21 February 2023)
  45. NEUROPATHY-POLYNEUROPATHY‏‎ (03:41, 21 February 2023)
  46. STROKE-BRUNNSTROM STAGES OF MOTOR RECOVERY‏‎ (03:41, 21 February 2023)
  47. CLINICAL-CAUSES OF BILATERAL BLINDNESS‏‎ (03:41, 21 February 2023)
  48. NCS-NORMAL MOTOR VALUES‏‎ (03:41, 21 February 2023)
  49. PARKINSONS & PARKINSONISM-LSVT EVIDENCE‏‎ (03:41, 21 February 2023)
  50. MND-FATIGUE MANAGEMENT‏‎ (03:41, 21 February 2023)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)